Business
Transgene Further Strengthens Scientific Advisory Board with Appointments of Renowned Cancer Immunotherapy Experts Antoine Italiano and Ignacio Melero
Strasbourg, France, January 23, 2026, 8:00 a.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announced the appointment of two additional key scientific advisors to its Scientific Advisory Board, Prof. Antoine Italiano, MD, PhD, and Prof. Ignacio Melero, MD, PhD, further strengthening its scientific leadership. “Antoine and Ignacio are world leaders in precision medicine, immune-oncology and cancer immu
About this update from Transgene Sa
[{"type":"image","alt":"Transgene S.A.","displaySize":"","headline":null,"caption":"Transgene S.A.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":61,"url":"https://media.zenfs.com/en/globenewswire.com/c8cdd55e9740420b0ba23689bb358d87"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/1Gql0Ywsm20IsoyH3I5M9Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTg1O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/c8cdd55e9740420b0ba23689bb358d87","width":300,"height":61}},"lazy":false},{"type":"text","content":"Strasbourg, France, January 23, 2026, 8:00 a.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announced the appointment of two additional key scientific advisors to its Scientific Advisory Board, Prof. Antoine Italiano, MD, PhD, and Prof. Ignacio Melero, MD, PhD, further strengthening its scientific leadership.","length":421,"tagName":"p"},{"type":"text","content":"“Antoine and Ignacio are world leaders in precision medicine, immune-oncology and cancer immunotherapy, and will bring considerable expertise to Transgene,” said Alessandro Riva, Transgene’s Chairman and CEO. “We are privileged to have them on board and look forward to working together as we accelerate the development of myvac®, our individualized neoantigen therapeutic vaccines platform and take the next important steps in the clinical development of our other viral vector-based cancer vaccine candidates.”","length":512,"tagName":"p"},{"type":"text","content":"Antoine Italiano, MD, PhD, is a renowned medical oncologist specializing in early drug development and precision medicine. He serves as Head of the Department of Medicine at Institut Bergonié in Bordeaux, France and leads the Precision Medicine program at Gustave Roussy in Paris, France.Prof. Italiano has been the Principal Investigator for over 50 Phase I trials and more than 40 Phase II and III clinical trials over the past five years. His research focuses on immuno-oncology, targeted therapies, and translational research, particularly in rare tumors such as sarcomas. He earned his PhD in Molecular Cell Biology in 2008 and completed a postdoctoral fellowship at Memorial Sloan Kettering Cancer Center in New York.Prof. Italiano is a member of ASCO, AACR, and ESMO, and regularly reviews ...